Publications by authors named "Garcia-Aparicio A"
The leading cause of blindness due to non-infectious uveitis is cystoid macular edema (CME). Behçet's disease (BD) is one of the most commonly conditions related to CME. To compare the effectiveness and safety of adalimumab (ADA), infliximab (IFX) and certolizumab (CZP) in refractory CME due to BD.
View Article and Find Full Text PDFArticle Synopsis
- * Among 46 patients, conjunctivitis (56.5%) and uveitis (50%) were the most common eye conditions, with cataracts and posterior synechiae being the primary structural complications.
- * The findings indicate that this cohort experienced less severe eye involvement compared to previous studies primarily focused on children, with effective treatment leading to good visual outcomes for most patients.
Reduction of disease activity, corticosteroids use, and healthcare resource utilisation in patients with systemic lupus erythematosus treated with belimumab in clinical practice settings: OBSErve Spain multicentre study.
Reumatol Clin (Engl Ed)
June 2023
Introduction And Objectives: This OBSErve Spain study, a part of the international OBSErve programme, evaluated belimumab real-world use and effectiveness following 6 months of treatment in patients with active systemic lupus erythematosus (SLE) in clinical practice in Spain.
Materials And Methods: In this retrospective, observational study (GSK Study 200883), eligible patients with SLE receiving intravenous belimumab (10mg/kg) had their disease activity (physician assessed), SELENA-SLEDAI scores, corticosteroid use, and healthcare resource utilisation (HCRU), assessed after 6 months of treatment versus index (belimumab initiation) or 6 months pre-index.
Results: Overall, 64 patients initiated belimumab, mainly due to ineffectiveness of previous treatments (78.
Cardiovascular Screening Practices and Statin Prescription Habits in Patients with Psoriasis among Dermatologists, Rheumatologists and Primary Care Physicians.
Acta Derm Venereol
March 2023
Patients with psoriasis have a higher prevalence of cardiovascular risk factors. This study evaluated cardiovascular screening practices and statin prescribing habits among dermatologists, rheumatologists and primary care physicians (PCPs) through an online questionnaire, which was distributed through the Spanish scientific societies of the above-mentioned specialties. A total of 299 physicians (103 dermatologists, 94 rheumatologists and 102 PCPs) responded to the questionnaire.
View Article and Find Full Text PDFObjectives: To evaluate effectiveness and safety of certolizumab pegol (CZP) in uveitis due to immune-mediated inflammatory diseases (IMID).
Methods: Multicentre study of CZP-treated patients with IMID uveitis refractory to conventional immunosuppressant. Effectiveness was assessed through the following ocular parameters: best-corrected visual acuity, anterior chamber cells, vitritis, macular thickness and retinal vasculitis.
Complications of uveitis in a Spanish population, UveCAM study.
Arch Soc Esp Oftalmol (Engl Ed)
May 2022
Objective: To estimate the population frequency of uveitis complications and to evaluate their main risk factors in the patients with uveitis from the UVECAM study.
Patients And Methods: Development of complications in 386 patients with uveitis in the whole health area of the province of Toledo (UVECAM study) during a period of 1 year. Description of complications and study of their possible determinants by means of multivariate regression models.
Article Synopsis
- Non-infectious uveitis is a complex condition that can be debilitating, often treated with immunosuppressive drugs, either alone or in combination, though the effectiveness of these strategies has not been directly compared.
- The CoTHEIA study is a significant research project designed to evaluate the safety, efficacy, and cost-effectiveness of methotrexate, adalimumab, and their combination in treating non-infectious non-anterior uveitis, involving 192 participants over a 52-week period.
- Ethical approvals are in place for the study, which will also employ machine learning to identify patient subgroups based on treatment response, and there are plans to widely disseminate the findings to various stakeholders.
Objective: Choroidal thickness (CT) has been evaluated as a marker of systemic inflammation in ankylosing spondylitis (AS). This study evaluates the CT of AS patients before and after 6 months of biological treatment.
Methods: This longitudinal multicenter study evaluated CT in 44 AS patients.
Article Synopsis
- * The review included 49 studies and found significant variability in prevalence and incidence, with an overall incidence rate of 50.45 cases per 100,000 people, affected by geographic differences.
- * Factors such as study methodology and definitions of uveitis contributed to substantial differences in reported rates, indicating that many studies may not be widely applicable or representative of the general population.
Objective: To assess the efficacy of abatacept (ABA) in RA patients with interstitial lung disease (ILD) (RA-ILD).
Methods: This was an observational, multicentre study of RA-ILD patients treated with at least one dose of ABA. ILD was diagnosed by high-resolution CT (HRCT).
Objectives: Digestive involvement (DI) has been reported in 10-30% of primary Sjögren's syndrome (pSS) patients, and few studies have systematically analysed the prevalence of DI in pSS patients. The aim of this study was to describe DI prevalence in pSS patients from the Sjögrenser Study, and to analyse its clinical associations.
Methods: All patients included in the Sjögrenser study, a Spanish multicentre randomised cohort, containing demographic, clinical and histologic data, have been analysed retrospectively.
Objective: To estimate the prevalence of uveitis and to describe its etiologic and anatomical patterns based on a population study carried out in a Spanish region.
Material And Methods: A cross-sectional, descriptive, population-based multicenter study was conducted. The selection criteria consisted of having a diagnosis of uveitis.
Graves' orbitopathy (GO) is the most common extrathyroidal manifestation of Graves' disease (GD). Our aim was to assess the efficacy and safety of Tocilizumab (TCZ) in GO refractory to conventional therapy. This was an open-label multicenter study of glucocorticoid-resistant GO treated with TCZ.
View Article and Find Full Text PDFArticle Synopsis
- - The study investigated factors linked to osteoporosis (OP) and fragility fractures in patients with primary Sjögren syndrome (pSS) using data from 437 patients across 33 Spanish rheumatology departments.
- - Findings revealed that 18.5% of the participants had OP, with significant associations found between OP and factors such as age, duration of the disease, and past corticosteroid treatment.
- - The analysis indicated that both age and disease duration were also associated with fragility fractures, highlighting the increased risk for patients with pSS as they get older and as their condition progresses.
Purpose: We assessed the efficacy and safety of biologic therapy in severe and refractory Peripheral Ulcerative Keratitis (PUK).
Design: Open-label multicenter study of biologic-treated patients with severe PUK refractory to conventional immunosuppressive drugs.
Subjects: We studied 34 patients (44 affected eyes) (24 women/10 men; mean age, 55.
Background And Objective: Ankylosing spondylitis (AS) is an inflammatory disease, and choroidal thickness (CT) has been proposed and evaluated as a potential marker of systemic inflammation associated with AS and other inflammatory diseases. This study compared CT measurements taken from patients with severe AS disease activity without eye inflammation with those taken from healthy subjects.
Methods: This cross-sectional, multicenter study compared CT in 44 patients with high AS disease activity, and no history of eye inflammation with CT in 44 matched healthy subjects aged between 18 and 65 years.
Article Synopsis
- The study aimed to evaluate the drug retention rate (DRR) and the factors influencing the discontinuation of adalimumab (ADA) treatment for noninfectious uveitis (NIU) in real-world settings across Spain.
- A total of 392 patients were analyzed, with a median follow-up of about 49 months, revealing a DRR of 93% at 6 months but dropping to about 54% after 5 years; discontinuation reasons included lack of efficacy and adverse events.
- The research employed various statistical methods to analyze predictors for discontinuation, finding that starting ADA in non-biotherapy-naive patients was associated with shorter drug retention time.
Objective: To compare the efficacy of infliximab (IFX) versus adalimumab (ADA) as a first-line biologic drug over 1 year of treatment in a large series of patients with refractory uveitis due to Behçet's disease (BD).
Methods: We conducted an open-label multicenter study of IFX versus ADA for BD-related uveitis refractory to conventional nonbiologic treatment. IFX or ADA was chosen as the first-line biologic agent based on physician and patient agreement.
Purpose: To assess efficacy, safety, and cost-effectiveness of adalimumab (ADA) therapy optimization in a large series of patients with uveitis due to Behçet disease (BD) who achieved remission after the use of this biologic agent.
Design: Open-label multicenter study of ADA-treated patients with BD uveitis refractory to conventional immunosuppressants.
Subjects: Sixty-five of 74 patients with uveitis due to BD, who achieved remission after a median ADA duration of 6 (range, 3-12) months.
Background: Reducing the dose of biological therapy (BT) when patients with immune-mediated arthritis achieve a sustained therapeutic goal may help to decrease costs for national health services and reduce the risk of serious infection. However, there is little information about whether such a decision can be applied universally. Therefore, the objective of this study was to develop appropriateness criteria for reducing the dose of BT in patients with rheumatoid arthritis (RA), axial spondyloarthritis (axSpA), and peripheral spondyloarthritis (pSpA).
View Article and Find Full Text PDFObjectives: To assess the efficacy of other biologic therapies, different from infliximab (IFX) and adalimumab (ADA), in patients with Behçet's disease uveitis (BU).
Methods: Multicenter study of 124 patients with BU refractory to at least one standard immunosuppressive agent that required IFX or ADA therapy. Patients who had to be switched to another biologic agent due to inefficacy or intolerance to IFX or ADA or patient's decision were assessed.
Objective: To compare the prevalence of the main comorbidities in 2 large cohorts of patients with primary Sjögren's syndrome (SS) and systemic lupus erythematosus (SLE), with a focus on cardiovascular (CV) diseases.
Methods: This was a cross-sectional multicenter study where the prevalence of more relevant comorbidities in 2 cohorts was compared. Patients under followup from SJOGRENSER (Spanish Rheumatology Society Registry of Primary SS) and RELESSER (Spanish Rheumatology Society Registry of SLE), and who fulfilled the 2002 American-European Consensus Group and 1997 American College of Rheumatology classification criteria, respectively, were included.
PurposeTo develop and validate a Bayesian belief network algorithm for the differential diagnosis of anterior uveitis.Patients and methodsThe 11 most common etiologies were included (idiopathic, ankylosing spondylitis, psoriasic arthritis, reactive arthritis, inflammatory bowel diseases, sarcoidosis, tuberculosis, Behçet, Posner-Schlossman syndrome, juvenile idiopathic arthritis (JIA), and Fuchs' heterochromic cyclitis). Frequencies of association between factors and etiologies were retrieved from a systematic review of the literature.
View Article and Find Full Text PDFObjective: To estimate the cost-effectiveness of belimumab in patients with systemic lupus erythematosus (SLE) presenting positive biomarkers and active disease despite standard treatment (ST), from the Spanish social perspective.
Methods: A microsimulation model was used to estimate the cost-effectiveness of belimumab plus ST versus ST alone. A treatment duration of two years with a life-time horizon were considered.